Core Points - The company held the third meeting of the 2022 employee stock ownership plan on August 14, 2025, to discuss adjustments to the management committee [1] - The meeting approved the election of Mr. Zhou Qin to the management committee following the resignation of Ms. Qian Liping due to a job adjustment [1] - The management committee now consists of Mr. Zhou Qin, Mr. Li Jia, and Ms. Li Lei, with their term aligned with the duration of the employee stock ownership plan [1] - Mr. Zhou Qin has no affiliations with the company's major shareholders or management, ensuring no conflicts of interest [1]

General Provisions - The company establishes a management system for the resignation of directors and senior management to promote healthy and sustainable development [1] - Applicable personnel include directors (including independent directors), the president, vice presidents, financial officers, board secretaries, and other senior management recognized by the company's articles of association [1] Resignation Circumstances and Procedures - Directors and senior management can resign before their term ends, with the resignation effective upon notification to the company [2] - The company must complete the election of new directors within sixty days of a resignation to ensure compliance with legal and regulatory requirements [2] - Resignation procedures include a handover of responsibilities and an internal audit before leaving [2][3] Responsibilities and Obligations of Resigning Directors and Senior Management - Resigning directors and senior management remain liable for their duties performed during their tenure, and their obligations regarding confidentiality and commitments continue post-resignation [3][4] - The company must pursue accountability for any violations of commitments or actions that harm the company's interests [3][4] Shareholding Management of Resigning Directors and Senior Management - Directors and senior management are prohibited from transferring their shares for six months after resignation [4][5] - There are restrictions on the percentage of shares that can be transferred annually during and after their term [4][5] Accountability Mechanism - The board of directors will review and determine accountability measures for any resigning directors or senior management who fail to fulfill their commitments [6] - Resigning individuals can appeal the accountability decisions within fifteen days of notification [6] Supplementary Provisions - Any matters not covered by this system will follow relevant laws, regulations, and the company's articles of association [6]

证券代码：002019 证券简称：亿帆医药 公告编号：2025-052 亿帆医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）第八届董事会任期已届满，根 据《公司法》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律 监管指引第1号—主板上市公司规范运作》等相关法律法规、规范性文件及《公 司章程》的有关规定，经公司第八届董事会提名委员会资格审查，公司于2025 年8月13日召开第八届董事会第十八次会议，审议通过了《关于董事会换届选举 非独立董事的议案》《关于董事会换届选举独立董事的议案》，现将具体情况公 告如下： 一、董事会换届选举情况 根据《公司法》和《公司章程》的相关规定，公司第九届董事会由6名董事 组成，其中非独立董事3名，独立董事2名，职工代表董事1名。 经公司第八届董事会提名委员会资格审查，第八届董事会第十八次会议审议， 董事会同意提名程先锋先生、林行先生、冯德崎先生为公司第九届董事会非独立 董事候选人；提名曾玉红女士、刘梅娟女士为公司第九届董事会独立董事候选人。 上述简历详见下文附件。 ...

Core Viewpoint - Yifan Pharmaceutical Co., Ltd. has nominated Liu Meijuan as a candidate for the independent director of its ninth board of directors, ensuring compliance with relevant regulations and qualifications for independent directors [1][8]. Summary by Sections Nomination Process - The nomination of Liu Meijuan was made after a thorough review of her professional background, education, qualifications, and any potential conflicts of interest [1]. - The nominee has agreed in writing to serve as an independent director candidate [1]. Compliance with Regulations - The nominee meets the qualifications and independence requirements set forth by the Company Law of the People's Republic of China and the Shenzhen Stock Exchange [1][2]. - The nominee has participated in training and obtained relevant certification recognized by the stock exchange [2]. Independence Assurance - The nominee does not have any close relationships that could affect her independent performance [1]. - The nominee and her immediate family do not hold more than 1% of the company's issued shares and are not part of the top ten shareholders [5][6]. Commitment to Responsibilities - The nominator guarantees the truthfulness and completeness of the statements made regarding the nominee's qualifications [8]. - The nominator commits to report any changes in the nominee's independence status during her tenure as an independent director [8].

亿帆医药股份有限公司 YIFAN PHARMACEUTICAL CO.,LTD. 关联交易决策制度 二 0 二五年八月修订 关联交易决策制度 关联交易决策制度 第二章 关联关系和关联人 第三条 关联关系是指公司控股股东、实际控制人、董事、高级管理人员与 其直接或者间接控制的企业之间的关系，以及可能导致公司利益转移的其他关系。 第四条 公司关联人包括关联法人（或者其他组织）和关联自然人。 （二）由前项所述法人（或者其他组织）直接或者间接控制的除上市公司及 其控股子公司以外的法人（或者其他组织）； （三）持有上市公司 5%以上股份的法人（或者其他组织）及其一致行动人； （四）由本制度所列上市公司的关联自然人直接或者间接控制的，或者担任 董事（不含同为双方的独立董事）、高级管理人员的，除上市公司及其控股子公 司以外的法人（或者其他组织）； 具有下列情形之一的法人或者其他组织，为上市公司的关联法人（或者其他 组织）： （一）直接或者间接地控制上市公司的法人（或者其他组织）； 第一章 前 言 第一条 为保证亿帆医药股份有限公司（以下简称"公司"、"上市公 司"）与关联方之间的关联交易符合公平、公正、公开的原则，确保公司 ...

内幕信息知情人登记管理制度 亿帆医药股份有限公司 YIFAN PHARMACEUTICAL CO.,LTD. 内幕信息知情人登记管理制度 （二 O 二五年八月修订） 内幕信息知情人登记管理制度 目 录 内幕信息知情人登记管理制度 第一章 总则 第一条 为进一步规范亿帆医药股份有限公司（以下简称"公司"）内幕信 息管理，加强内幕信息保密工作，建立内幕信息知情人档案，防范内幕交易，根 据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司信息披露管 理办法》《上市公司监管指引第 5 号—上市公司内幕信息知情人登记管理制度》 《深圳证券交易所股票上市规则》等有关法律、法规、规章和《亿帆医药股份有 限公司公司章程》（以下简称"《公司章程》"）的有关规定，特制定本制度。 第二条 本制度所称内幕信息是指根据《证券法》第五十二条规定，涉及 公司的经营、财务或者对公司证券市场价格有重大影响的尚未在证券交易所网站 和符合中国证券监督管理委员会（以下简称"中国证监会"）规定条件的媒体正 式公开披露的信息。 第三条 本制度适用于公司及下属各部门、分公司、控股子公司及公司能 够对其实施重大影响的参股公司以及本制度规定的其他内幕 ...

Core Viewpoint - The document outlines the fundraising management measures of Yifan Pharmaceutical Co., Ltd., emphasizing the need for strict adherence to regulations and efficient use of raised funds to protect investors' rights and interests [3][4][11]. Summary by Sections General Principles - The purpose of the fundraising management measures is to standardize the management and use of raised funds, improve efficiency, and protect investors' rights [3]. - The term "raised funds" refers to money obtained through the issuance of stocks or other equity-like securities, excluding funds raised for equity incentive plans [3]. - The company must use raised funds prudently and ensure that their use aligns with the commitments made in the issuance application documents [3][4]. Fund Storage - The company is required to open a special account for raised funds, which must be approved by the board of directors, and these funds should not be mixed with other funds [5][6]. - A tripartite supervision agreement must be signed with the underwriter or independent financial advisor and the bank holding the funds within one month of the funds being received [6][7]. Fund Usage - Raised funds should primarily be used for the company's main business and must not be used for high-risk investments or to provide financial assistance to others [8][9]. - If the investment project cannot be completed within the original timeframe, the company must disclose the reasons and the current status of the funds [8][9]. - Any changes in the use of raised funds must be approved by the board and disclosed promptly [9][10]. Supervision and Reporting - The company’s accounting department must maintain detailed records of the use of raised funds, and internal audits should be conducted quarterly [28][29]. - The board must regularly review the status of the raised funds and report any significant discrepancies in usage compared to the planned investment [29][30]. - Independent auditors must verify the annual report on the management and use of raised funds, and any adverse conclusions must be addressed by the board [20][21].

亿帆医药股份有限公司 YIFAN PHARMACEUTICAL CO.,LTD. 公司章程 （二 O 二五年八月修订） | 第一章 总 | 则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 4 | | 第一节 | 股份发行 4 | | 第二节 | 股份增减和回购 5 | | 第三节 | 股份转让 6 | | 第四章 | 股东和股东会 7 | | 第一节 | 股东的一般规定 7 | | 第二节 | 控股股东和实际控制人 10 | | 第三节 | 股东会的一般规定 11 | | 第四节 | 股东会的召集 13 | | 第五节 | 股东会的提案与通知 14 | | 第六节 | 股东会的召开 16 | | 第七节 | 股东会的表决和决议 18 | | 第五章 | 董事和董事会 23 | | 第一节 | 董事的一般规定 23 | | 第二节 | 董事会 26 | | 第三节 | 独立董事 29 | | 第四节 | 董事会专门委员会 32 | | 第六章 | 高级管理人员 34 | | 第七章 | 财务会计制度、利润分配和审计 35 | | 第一节 | 财务会计制度 3 ...

董事会议事规则 亿帆医药股份有限公司 YIFAN PHARMACEUTICAL CO.,LTD. 董事会议事规则 （二 O 二五年八月修订） | 第一章 总 | 则 | 3 | | --- | --- | --- | | 第二章 董事会职权 | | 4 | | 第三章 董 | 事 | 6 | | 第四章 | | 董事会会议的召集、通知及召开 9 | | 第五章 | | 董事会会议的表决及决议 11 | | 第六章 | 董事会记录 | 13 | | 第七章 附 | 则 | 14 | 董事会议事规则 第一章 总 则 第一条 为规范亿帆医药股份有限公司(以下简称"公司")董事会行为，完 善法人治理结构，维护公司、股东的合法权益，确保董事会的工作效率和科学决 策，根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共 和国证券法》《上市公司治理准则》《上市公司章程指引》《上市公司独立董事 管理办法》《深圳证券交易所股票上市规则》（以下简称"《上市规则》"）、 《上市公司自律监管指引第 1 号——主板上市公司规范运作》和《亿帆医药股份 有限公司章程》（以下简称"《公司章程》"）等有关规定，特制定本规则。 ...

内幕信息知情人登记管理制度 亿帆医药股份有限公司 YIFAN PHARMACEUTICAL CO.,LTD. 内幕信息知情人登记管理制度 （二 O 二五年八月修订） | 第一章 | 总则 3 | | --- | --- | | 第二章 | 内幕信息及内幕信息知情人的范围 3 | | 第三章 | 内幕信息的保密管理 5 | | 第四章 | 内幕信息知情人登记备案管理 6 | | 第五章 | 内幕信息知情人买卖公司证券的管理 11 | | 第六章 | 责任追究措施 11 | | 第七章 | 附则 12 | 第三条 本制度适用于公司及下属各部门、分公司、控股子公司及公司能 够对其实施重大影响的参股公司以及本制度规定的其他内幕信息知情人。 第二章 内幕信息及内幕信息知情人的范围 第四条 公司内幕知情人的范围包括但不限于以下内容： （一）发生可能对公司的股票交易价格产生较大影响的重大事件，包括： 内幕信息知情人登记管理制度 1、公司的经营方针和经营范围的重大变化； 第一章 总则 第一条 为进一步规范亿帆医药股份有限公司（以下简称"公司"）内幕信 息管理，加强内幕信息保密工作，建立内幕信息知情人档案，防范内幕交易，根 据 ...